All In Biotech

NDA 050317 · Pfizer

Lincocin

Lincomycin Hydrochloride · Injection

Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Dec 29, 1964

Approved uses

1

Original approval plus efficacy supplements

Registered trials

154

34 Phase 3, 15 recruiting

FAERS reports

170

105 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including LINCOCIN and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because lincomycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial...

What it is approved for

From the label in effect Mar 10, 2025.

INDICATIONS AND USAGE LINCOCIN is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. LINCOCIN may be administered concomitantly with other antimicrobial agents when indicated. LINCOCIN is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of LINCOCIN and other antibacterial drugs, LINCOCIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 29, 1964 Original approval
1 products under this application
  • LINCOCIN · LINCOMYCIN HYDROCHLORIDE EQ 300MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Lincomycin" as an intervention, any sponsor and status, largest first.

All 154 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity54
  • dyspnoea12
  • diarrhoea11
  • rash10
  • tachycardia9
  • abdominal pain8
  • dizziness8
  • drug ineffective8
  • nausea8
  • pain8
  • pyrexia8
  • vomiting8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
200512
20062
20075
20083
20093
20107
20116
201216
201311
20145
20152
201612
201713
201817
201914
20202
20217
20226
202310
20247
20254
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Feb 25, 2026

    Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Nov 6, 2026

    Lincocin, Injection, 10 mL multiple dose vial (NDC 0009-0107-04). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lincocin (Lincomycin HCl)

2024 spending

$997

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$13.11 per unit

View as table
YearSpending
2020$2,724
2021$1,777
2022$1,056
2023$950
2024$997

Part B: Lincocin* (Lincomycin HCL*) · HCPCS J2010

2024 spending

$232K

Beneficiaries

11,186

16,070 claims

Per beneficiary

$21

2024 ASP limit $9.87 per unit

View as table
YearSpending
2020$352,794
2021$299,783
2022$268,881
2023$258,596
2024$231,776

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 86 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.